Veri MedTech Holdings, Inc.

S-1/A amended

Price $4.00 · 3,750,000 shares · Gross proceeds $15,000,000

Veri MedTech Holdings, Inc. is conducting a firm commitment public offering of up to 3,750,000 shares of common stock at $4 per share. The company intends to list on NASDAQ but faces risks related to market volatility, reliance on key personnel, and regulatory compliance. The offering includes underwriter warrants and a 45-day over-allotment option. The company is an emerging growth company with a controlled ownership structure post-offering.

S-1/A amended

Veri MedTech Holdings, Inc. is conducting a firm commitment public offering of up to [●] shares of common stock, with an estimated public offering price between $[●] to $[●] per share. The company aims to list its shares on the NYSE American Market under the ticker symbol 'VRHI' following the offering. The filing highlights the company's status as a smaller reporting company and emerging growth company, with implications for reduced reporting requirements. The offering includes underwriter warrants and a 45-day option for additional shares, with proceeds intended to fund operations and growth initiatives.

S-1/A amended

Veri MedTech Holdings, Inc. (VERI) is conducting an amended S-1/A filing for its initial public offering (IPO) of common stock, with an updated offering price range and underwriting terms. The filing includes revised details on underwriter compensation, reimbursement obligations, and the lead underwriter. The company remains a holding company with operations through subsidiaries, and the IPO aims to list shares on the NYSE American Market, though approval is not guaranteed.

S-1 filed

Veri MedTech Holdings, Inc. (VERI) is a holding company conducting operations through wholly-owned subsidiaries, offering medical marijuana services via a healthcare technology platform. The company is initiating a public offering of up to [●] shares of common stock, priced between $[●] and $[●], with an intent to list on the NYSE American Market. VERI is classified as a smaller reporting company and emerging growth company, benefiting from reduced reporting requirements. The offering includes underwriter warrants and a 45-day over-allotment option. The company emphasizes its reliance on key personnel and faces risks related to regulatory compliance, market competition, and product commercialization.